First biosimilar approved to treat multiple sclerosis

The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.

Diseases, Conditions, Syndromes

How the herpes virus HCMV deceives its host cells

Herpes viruses are treacherous: once you are infected, you can never get rid of the virus. This is because herpes viruses lie dormant in certain host cells in the body for a lifetime. Almost every adult unknowingly carries ...

Diseases, Conditions, Syndromes

Investigating acute hepatitis of unknown origin in children

Since Fall 2021, an increasing number of unexplained cases of severe acute hepatitis have been reported in children. Epidemiologic investigation is ongoing, and, to date, a cause of these outbreaks has not been identified. ...


Study shows immune cells have a backup mechanism

The enzyme TBK1 is an important component of the innate immune system that plays a critical role in the defense against viruses. Upon mutation-induced loss of TBK1 function, patients show an increased susceptibility to viral ...

Oncology & Cancer

Severe herpesvirus infection beats adult T-cell leukemia/lymphoma

In a recently published editorial in the journal Genes & Cancer, researcher Tatsuro Jo from the Japanese Red Cross Nagasaki Genbaku Hospital's Department of Hematology discussed aggressive type adult T-cell leukemia/lymphoma ...

page 1 from 12